Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period

Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period

Abstract Introduction Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) offers an effective alternative to daily oral antiretroviral therapy (ART) for people living with human immunodeficiency virus (PLWH), especially those with adherence challenges. Despite increasing use of LA-CAB/RPV, long-term r...

Full description

Saved in:
Bibliographic Details
Main Authors: Catharina Dannenberg, Hanna Matthews, Anja Hüfner, Gabriel V. Drewinski, Anna Koval, Sabine Jordan, Stefan Schmiedel, Julian Schulze zur Wiesch, Olaf Degen
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Infectious Diseases and Therapy
Subjects:
Adherence
Cabotegravir (CAB)
Efficacy
HIV treatment
Injectables
Long-acting (LA) HIV therapy
Online Access:https://doi.org/10.1007/s40121-025-01178-3
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items